Soeren Mattke, MD, DSc

Looking to the future of Alzheimer disease treatment, the panel discusses key takeaways on the evolving therapeutic landscape.

Experts discuss how payers can prepare for new treatments and plan adequate coverage for patients with Alzheimer disease.

An overview of how disease-modifying treatments for Alzheimer disease can impact medical costs and caregiver burden.

The panel discusses emerging therapies for Alzheimer disease that are currently in development, including donanemab, subcutaneous lecanemab, and ALZ-801.

A comprehensive discussion on the value of therapies for Alzheimer disease based on cost vs outcome, and unmet needs in the overall treatment landscape.

Experts provide their perspectives on clinical factors taken into consideration when deciding on a treatment plan for a patient with Alzheimer disease.

Experts on Alzheimer disease discuss how the introduction of disease-modifying therapies has impacted the treatment landscape.

The panel provides insights on the economic impact of advanced approaches for diagnosing Alzheimer disease, highlighting how payers approach increased costs.

Focusing on the diagnosis of Alzheimer disease, the panel discusses key diagnostic criteria, testing practices, and the role of genetic testing.

B. Joy Snider, MD, PhD, discusses the benefits of early diagnosis of Alzheimer disease and how it can impact the patient journey.

The expert panel offers comprehensive insights on the patient journey for people with Alzheimer disease, highlighting symptoms, challenges, and the diagnostic process.

The panel provides an overview of genetic factors associated with Alzheimer disease and the genetic mutations that contribute to the pathophysiology of the disease.

B. Joy Snider, MD, PhD, gives an overview of the pathophysiology of Alzheimer disease, highlighting recent advances in the field.

A panel of experts on Alzheimer disease provide insights on symptoms the patient might experience and the impact of the disease on patients, families, caregivers, and the health care system.

This study shows that health plans use chronic care management programs as standard components of the overall approach to manage the health of their members.

Analysis of studies of worksite wellness programs suggested mixed impact on health-related behaviors and cost, with insufficient evidence regarding absenteeism and mental health.

In a health plan–sponsored e-prescribing initiative, participating PCPs' mean e-prescribing rate was 1 prescription per 4 pharmacy claims, but some PCPs achieved high use.

Integrated health management programs combining disease prevention and disease management services, although popular with employers, may not save money, at least in their first year.

Recent events have cast doubt on the ability of disease management to reduce medical cost and to affect the quality of care.